Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1613, 2007-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Dasatinib tops imatinib for CML on economic level
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. :
Access to resources
Recommend
Dasatinib: a once-daily option for imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. :
Dasatinib a START-R in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. :
Dasatinib off to a good start in imatinib-resistant CML
Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. :
Nilotinib, dasatinib or imatinib in CML: no clear winner
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 656, 2012-01 ,pp. :